Does molecular monitoring matter in early-stage breast cancer?

Sci Transl Med. 2015 Aug 26;7(302):302fs35. doi: 10.1126/scitranslmed.aac9445.

Authors

Tilak K Sundaresan¹, Daniel A Haber²

Affiliations

¹ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
² Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. dhaber@mgh.harvard.edu.

PMID: 26311727
DOI: 10.1126/scitranslmed.aac9445

Abstract

Serial monitoring of circulating tumor DNA predicts recurrence after treatment for localized breast cancer (Garcia-Murillas et al., this issue).

Copyright © 2015, American Association for the Advancement of Science.

Publication types

Comment

MeSH terms

Breast Neoplasms / genetics*
DNA, Neoplasm / genetics*
Female
Humans
Mutation*

Substances

DNA, Neoplasm